Conflict of Interest Disclosures: Dr Mehra reported receiving travel support and consulting fees, paid to Brigham and Women’s Hospital, from Abbott; fees for serving on a steering committee from Medtronic and Janssen (Johnson & Johnson); fees for serving on a data and safety monitoring board from Mesoblast; consulting fees from Portola, Bayer, and Triple Gene; and fees for serving as a scientific board member from NuPulseCV, Leviticus, and FineHeart. Dr Bhatt disclosed the following relationships—advisory board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, and Regado Biosciences; board of directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; chair: American Heart Association Quality Oversight Committee; data monitoring committees: Baim Institute for Clinical Research, Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, and Population Health Research Institute; honoraria: American College of Cardiology, Baim Institute for Clinical Research, Belvoir Publications, Duke Clinical Research Institute, HMP Global, Journal of the American College of Cardiology, Medtelligence/ReachMD, Population Health Research Institute, Slack Publications, Society of Cardiovascular Patient Care, and WebMD; other: Clinical Cardiology, NCDR-ACTION Registry Steering Committee, VA CART Research and Publications Committee; research funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, and the Medicines Company; royalties: Elsevier; site co-investigator: Biotronik, Boston Scientific, St Jude Medical, and Svelte; trustee: American College of Cardiology; and unfunded research: FlowCo, Merck, Novo Nordisk, and Takeda. Dr Nasir reported being supported by the Jerold B. Katz Academy of Translational Research. Dr Califf reported serving on the corporate board for Cytokinetics; being the board chair for the People-Centered Research Foundation; and receiving personal fees for consulting from Merck, Amgen, AstraZeneca, Biogen, Genentech, Eli Lilly, and Boehringer Ingelheim; and receiving other funding from Verily Life Sciences and Google Health. No other disclosures were reported.